Skip to content
Screener

Maze Therapeutics MAZE Q1 2026 earnings

Reported May 12, 2026 · Before market open

Revenue$20.0MBeat by $9.4M
EPS-$0.45Miss by $0.02
Revenue estimate$10.6M
EPS estimate-$0.43

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$333.3K
EPS estimate-$0.79

Financials

Q1 2026

Income statement

See full
Revenue$20.0M—
Operating income-$26.6M+25.0%
Net income-$24.2M+26.2%
EPS (diluted)-$0.45+60.9%

Balance sheet

See full
Cash & equivalents$198.8M-32.5%
Total debt$61.2M+137%
Total equity$341.7M+17.0%
Total assets$419.7M+26.1%

Cash flow

See full
Operating cash flow-$39.1M-32.5%
CapEx$93.0K-68.9%
Free cash flow-$39.2M-31.5%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$1.47B—
Enterprise value$1.34B—

Returns & leverage

See full
Return on equity-38.7%—
Debt / equity0.2×+0.1×
Current ratio17.9×+1.8×

Segments

By geography

See full
US$20.0M—

FAQ

When did Maze Therapeutics report Q1 2026 earnings?
Maze Therapeutics (MAZE) reported Q1 2026 earnings on May 12, 2026 before market open.
What were Maze Therapeutics's Q1 2026 revenue and EPS?
Maze Therapeutics reported revenue of $20.0M and eps of $-0.45 for Q1 2026.
Did Maze Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $10.6M by $9.4M. EPS missed the consensus estimate of $-0.43 by $0.02.
How did Maze Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 60.9% from $-1.15.
Where can I find Maze Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-219398) and the 10-Q periodic report (0001193125-26-219430) directly on SEC EDGAR. The filing index links above go to sec.gov.